BioCina taps Mark Womack as CEO

Image credit: BioCina

Australian contract development and manufacturing organisation (CDMO) BioCina has appointed Mark Womack as the chief executive officer, who will oversee the continued growth, commercial strategy and organisational culture of the company.

This announcement follows the appointment of founding CEO Ian Wisenberg to the BioCina Board of Directors as executive chairman.

Womack has 30 years of experience in executive leadership, management consulting, and CDMO commercial operations, which he will contribute to BioCina.

According to the company, he has a track record of achieving excellent growth and profit in every role.

Most recently, Womack held the position of CEO of KBI Biopharma and Selexis SA, where he implemented a new commercial strategy that led to much larger transaction sizes and profitability while also generating a run rate of over 30 per cent year-over-year revenue growth in just six months.

Womack previously served as the CEO and managing director of Stelis Biopharma, where he led the development and implementation of a pure-play CDMO infrastructure, including an end-to-end biologics offering across multiple facilities.

He oversaw the company’s efforts in 2021 to construct and qualify a cutting-edge vaccine facility capable of clinical and commercial-scale manufacturing in record time.

Womack was also AGC Biologics’ CEO. His strong track record of enhancing organisational performance led to a roughly 300 per cent rise in sales in just two years.

Wisenberg expressed his excitement over Womack’s selection and noted that over the past two years, the team and investment expanded BioCina from a single-product commercial facility into “Australia’s highest quality biologics CDMO.”

“We are very fortunate to have someone with Mark’s vision and pedigree of growing high-value CDMOs to lead our company into its next phase,” Wisenberg said. 

BioCina said it recently increased its CDMO service offerings to include GMP plasmid DNA and R&D mRNA manufacturing to meet the rising demand for vaccines and pharmaceuticals on a global scale.

Womack on the other hand expressed his delight at his appointment to expand on all of the achievements the BioCina team had already achieved while leading a dedicated group of individuals.

“I’m tremendously excited to lead the highly talented and deeply committed BioCina team, and to build on all of the success they’ve achieved to date,” Womack noted. 

He added, “Leveraging BioCina’s core strengths, we will become a preeminent Global Biologics CDMO through industry-leading quality, a client-centric approach and on-time delivery of client programs.”